Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Enoblituzumab |
| Trade Name | |
| Synonyms | MGA271|MGA 271|MGA 271 |
| Drug Descriptions |
Enoblituzumab (MGA271) is an inhibitory monoclonal antibody against CD276 (B7-H3), which induces an anti-tumor immune response (PMID: 22615450). |
| DrugClasses | CD276 Antibody 21 |
| CAS Registry Number | 1353485-38-7 |
| NCIT ID | C97510 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Aldesleukin + Enoblituzumab + FT516 | Aldesleukin Enoblituzumab FT516 | 0 | 1 |
| Enoblituzumab | Enoblituzumab | 0 | 4 |
| Enoblituzumab + FT538 | Enoblituzumab FT538 | 0 | 1 |
| Enoblituzumab + Ipilimumab | Enoblituzumab Ipilimumab | 0 | 1 |
| Enoblituzumab + MGD013 | Enoblituzumab MGD013 | 0 | 1 |
| Enoblituzumab + Pembrolizumab | Enoblituzumab Pembrolizumab | 0 | 1 |
| Enoblituzumab + Retifanlimab | Enoblituzumab Retifanlimab | 0 | 1 |